ExploreWatchlistsPricing
  1. JP-listed companies
  2. RIBOMIC Inc.
  3. Financials
  4. Total liabilities

RIBOMIC Inc. (4591)

Market cap
¥2.6B
P/E ratio
-1.9x
Ribomics develops next-generation aptamer drugs using its proprietary RiboART System to treat unmet medical needs like achondroplasia and eye diseases.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal liabilities (Million JPY)YoY (%)
Mar 31, 2026135-5.00%
Mar 31, 2025142-8.73%
Mar 31, 2024156-21.82%
Mar 31, 2023199-23.50%
Mar 31, 2022261+122.75%
Mar 31, 2021117+31.73%
Mar 31, 202089-91.82%
Mar 31, 20191,086+988.76%
Mar 31, 2018100+74.68%
Mar 31, 201757-60.40%
Mar 31, 2016144-7.93%
Mar 31, 2015157

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat